Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMS1005 in Type 2 Diabetes
NCT07568678Phase 1Recruiting
- Sponsor
- Hua Medicine
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HMS1005 in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Hua Medicine. Primary endpoints: Incidence of adverse events at Day 19, Area under the plasma concentration versus time curve and 3 more. Started Dec 2025; status: recruiting.
02
Drugs
HMS1005
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07568678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07568678.